Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis

Full text
Author(s):
Show less -
Caridha, Diana [1] ; Vesely, Brian [1] ; van Bocxlaer, Katrien [2, 3] ; Arana, Byron [4] ; Mowbray, Charles E. [4] ; Rafati, Sima [5] ; Uliana, Silvia [6] ; Reguera, Rosa [7] ; Kreishman-Deitrick, Mara [1] ; Sciotti, Richard [1] ; Buffet, Pierre [8] ; Croft, Simon L. [2]
Total Authors: 12
Affiliation:
[1] Walter Reed Army Inst Res, Silver Spring, MD - USA
[2] London Sch Hyg & Trop Med, London - England
[3] Univ York, York Biomed Res Inst, Dept Biol, York, N Yorkshire - England
[4] Drugs Neglected Dis Initiat DNDi, Geneva - Switzerland
[5] Inst Pasteur Inst, Dept Immunotherapy & Leishmania Vaccine Res, Tehran - Iran
[6] Univ Sao Paulo, Biomed Sci Inst, Dept Parasitol, Sao Paulo, SP - Brazil
[7] Univ Leon, Dept Biomed Sci, Leon - Spain
[8] INTS, Lab Excellence GR Ex, UniteA Biol InteAgreAe Globule Rouge, Paris - France
Total Affiliations: 8
Document type: Review article
Source: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 11, n. SI, p. 106-117, DEC 2019.
Web of Science Citations: 1
Abstract

Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R \& D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles. (AU)

FAPESP's process: 15/09080-2 - Evaluation of candidate drugs for the treatment of Leishmaniasis in Brazil
Grantee:Silvia Reni Bortolin Uliana
Support type: Regular Research Grants